Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 7/20 | 0.69 |
| ▸ | FLT3 | P36888 | 3/20 | 0.61 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.48 |
| ▸ | RET | P07949 | 1/20 | 0.48 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | CSF1R | P07333 | 1/20 | 0.48 |
| ▸ | BRAF | P15056 | 2/20 | 0.48 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.47 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.47 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.47 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.46 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.46 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL669077 | 0.82 | RAF1 (0.81) | RAF1FLT3MAPK14ALDH1A1NTRK1 | |
| SCHEMBL668575 | 0.82 | RAF1 (0.81) | RAF1FLT3MAPK14ALDH1A1BRAF | |
| SCHEMBL667897 | 0.81 | RAF1 (1.00) | RAF1FLT3MAPK14ALDH1A1NTRK1 | |
| SCHEMBL13234433 | 0.81 | RAF1 (0.74) | RAF1FLT3MAPK14ALDH1A1NTRK1 | |
| SCHEMBL5571972 | 0.80 | RAF1 (0.76) | RAF1FLT3MAPK14ALDH1A1NTRK1 | |
| SCHEMBL5575094 | 0.79 | RAF1 (0.66) | RAF1FLT3MAPK14ALDH1A1NTRK1 | |
| SCHEMBL13234595 | 0.79 | RAF1 (0.71) | RAF1FLT3MAPK14ALDH1A1NTRK1 | |
| SCHEMBL5573475 | 0.79 | RAF1 (0.68) | RAF1FLT3MAPK14ALDH1A1NTRK1 | |
| SCHEMBL13234411 | 0.78 | MAPK14 (0.72) | RAF1FLT3MAPK14ALDH1A1NTRK1 | |
| SCHEMBL667912 | 0.78 | RAF1 (0.70) | RAF1FLT3MAPK14ALDH1A1NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120129893-A1 | Inhibition Of Raf Kinase Using Substituted Heterocyclic Ureas | DUMAS JACQUES (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120129893-A1 | Inhibition Of Raf Kinase Using Substituted Heterocyclic Ureas | DUMAS JACQUES (US) | 2012-05-24 | — | — | US | disclosed |
| US-20070244120-A1 | INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER HEALTHCARE LLC | 2007-10-18 | — | — | US | disclosed |
| US-20070244120-A1 | INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER HEALTHCARE LLC | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244120-A1 | INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS | BRAF, RAF1, ARAF | RAF1 2/4885FLT3 131/4885MAPK14 127/4885 |
| US-20120129893-A1 | Inhibition Of Raf Kinase Using Substituted Heterocyclic Ureas | BRAF, RAF1, ARAF | RAF1 2/4885FLT3 131/4885MAPK14 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.